BioAge Labs, a Berkeley, CA-based developer of a machine learning powered platform to measure human aging and accelerate drug discovery, raised $10.9M in Series A financing.
The round was led by the Andreessen Horowitz Bio Fund (with Dr. Vijay Pande joining the Board of Directors) with participation from Felicis Ventures, AME Cloud Ventures, PEAR Ventures, Caffeinated Capital, Elad Gil, and other angels.
The company intends to use the funds to build the team, refine and test its signatures of aging, and begin in vivo evaluation of drug candidates.
Led by Kristen Fortney, PhD, CEO, Chris Morrissey, PhD, Head of Bioinformatics, and Jonah Sinick, PhD, Head of Data Science, BioAge Labs initially targets specific diseases where aging is causal. However, its ultimate goal is to combat the suffering and disability caused by all aging-related diseases, and to restore both the quality and quantity of life in old age.
FinSMEs
29/07/2017